Abstract
Introduction
Gemcitabine hydrochloride is a pyrimidine nucleoside analog which is applied as a chemotherapeutic antimetabolite. Gemcitabine inhibits DNA replication by inhibiting DNA synthesis and by blocking repair mechanisms through masked chain termination. Additionally, gemcitabine exerts several other actions that self-potentiate its cytotoxic activity. Gemcitabine is usually well tolerated by the patients and its common associated side-effects are not severe, and include low grade myelotoxicity,¯u-like syndrome, fever, rash, swelling of the legs, nausea and vomiting. Gemcitabine has demonstrated signi® cant clinical activity and clinical bene® t response in a variety of tumors. 1± 4 Very limited data is available on the use of gemcitabine in soft tissue (STS) or bone sarcomas. Gemcitabine was found to be active on xenograft of STS growing in nude mice. 5, 6 Palliative effects of gemcitabine in a patient with osteosarcoma resistant to standard chemotherapy 7 and experience with gemcitabine in patients with a variety of progressive sarcomas 8 have been recently reported by our team. This report focuses on the effect of gemcitabine on bone sarcoma.
Treatment protocol
Eligibility criteria were recurrent or metastatic osteosarcoma, that either failed to respond to standard chemotherapy for metastatic or recurrent disease and progressed while on chemotherapy, or relapsed after having been treated with pre-operative or adjuvant chemotherapy and had demonstrated progressive disease over a period of 3 months. Standard chemotherapy for bone sarcoma had to include methotrexate (MTX), cisplatin (CDDP), adriamycin ADR and ifosmamide IFX. All the patients had to be 15 years or older, with a Karnofsky's performance status (KPS) of at least 40%, and life expectancy of at least 3 months. Any bone sarcoma type was permitted provided that there was measurable disease, and there were no central nervous system nor spinal cord involvement. Signed informed consent was mandatory (in case of patients younger than 18, parents also signed).
Baseline evaluation included interview and assessment of symptoms severity and quality of life, measurement and documentation of marker lesions by CT scan, ultrasound or plain X-rays, and complete blood count and biochemical serum analysis.
Treatment consisted of induction by gemcitabine 1000 mg/m2/w for 7 consecutive weeks, followed by 1 week rest. Response to induction course was assessed by interview (for clinical bene® t response and quality of life) and by repeated ancillary tests. If no progression was observed, maintenance by gemcitabine 1000 mg/m2/w for 3 weeks every 28 days was given until failure was clinically or radiologically evident. Evaluation of response, toxicity and quality of life, was performed every 3 months by interview, physical examination and ancillary tests, according to the WHO criteria. Progression was determined as deterioration in clinical symptoms, appearance of new lesions or enlargement of a lesion by at least 25% of its pre-treatment size. Treatment was to be stopped in case of life-threatening toxicity, progression of the disease, or on patient's refusal to continue.
Patients
Seven patients with primary extremity bone sarcoma, at age range of 15± 43 years, were enrolled from December 1996 through August 1999 into an ongoing phase II study on gemcitabine in soft tissue or bone sarcoma. 8 All the patients were heavily pre-treated by various agents according to their disease, such as adriamycin, ifosfamide, high-dose ifosfamide, methotrexate and etoposide.The involved sites were mainly the local tumor bed and lung. The main symptoms were pain and respirator y problems. Patient characteristics are detailed in Table 1 .
Results
The true objective response rate of osteosarcoma to gemcitabine was 0%. However, disease stabilization was observed in 5 out of 7 patients after having failed on previous treatments. Time to progression varied from 13 to 96 weeks. It should be noted that disease stabilization was accompanied by clinical bene® t response, i.e. improvement of performance status, alleviation of respiratory symptoms, alleviation of pain and reduction in narcotics consumption) and was observed only in those who also achieved a progression-free state.
All the patients who failed to respond to gemcitabine did not have any clinical bene® t response.The treatment was well tolerated by the patients. Hematological toxicity was the main concern in our patients, of whom the vast majority was heavily pre-treated. Other toxic effects included weakness, rash ascites (with no malignant cells in repeated taps), limb edema (deep vein thrombosis was excluded by Dopplerultrasound study), and low grade fever.
Discussion
Bone sarcomas carry poor prognosis. Close to one half of patients succumb to metastatic or locally advanced disease. Metastatic sarcoma is usually fatal and treatment options are rather limited. Median
Patients with metastatic sarcoma often are asymptomatic at the time that a radiograph or CT reveals metastases, and may remain free of symptoms for long periods of time.Thus, alleviation of symptoms is not an immediate concern in many patients, although disease progression is eventually inevitable.
Numerous drug combinations have been assessed in treated and untreated metastatic disease.The most effective of these have contained cisplatin, doxorubicin and high-dose methotrexate± leucovorin factor either as a two-or three-drug regimen; response rates of the order of 25± 35% have been obtained, although often based on rather small numbers. The most important studies on palliative chemotherapy in metastatic osteosarcoma include cyclophosphamide+ doxorubicin+dacarbazine (29 patients, response rate 24% ). The oncological problem starts after failure of these agents to affect the disease course. The patients, especially the younger, may still have considerable life expectancy and good performance status, and are eager to be treated, but the caring oncologist may have nothing to propose. There is a need for active and minimally toxic agents that can be given as second line treatment in patients with STS or bone sarcoma. This was the rationale to use gemcitabine in this hopeless population of patients with sarcoma.
The information given to patients before participation in such study, especially when no more standard therapy exists for young patient with strong life will, should give`controlled hope' but without illusions for cure.The patients were told that gemcitabine was highly experimental in osteosarcoma, that there was no literature on the topic, that the worldwide experience with the drug was achieved in other diseases, and that the expected toxicity was relatively mild.
Our results pointed to the important effect of gemcitabine treatment in heavily pre-treated patients with progressive bone sarcomas. Gemcitabine was found to be effective in achieving stabilization of osteosarcoma refractory to standard chemotherapy consisting mainly of adriamycin, high-dose methotrexate, cisplatin and ifosfamide. Although disease stabilization is generally accepted as failure of chemotherapy, in this series of cases it should be regarded as success due to noteworthy disease control, clinical bene® t response and low toxicity pro® le, especially in view of failure of the accepted drugs.
It is interesting to note that gemcitabine has shown activity in STS. In a recent study reported by our group 8 we have documented one partial response (leiomyosarcoma) and one minimal response (angiosarcoma), yielding an true objective response rate of 5.5%. An additional six patients achieved stabilization of disease, yielding an overall progression-free rate of 44%. The median time to progression was more than 27 weeks.
Patel et al. 13 reported their experience in patients with various types of STS that were given gemcitabine in a schedule similar to that in our trial. The best responses were observed, as in our study, in patients with angiosarcoma and leiomyosarcoma. The observations in these trials point to a possible role of gemcitabine in the treatment in angiosarcoma and leiomyosarcoma. In our study and in Patel's study, gemcitabine monotherapy was given in a schedule of 1 gr/m2/week for 3 weeks every 28 days. A different schedule is suggested by Spith-Schwalbe et al.:
14 200 mg/m 2 given on days 1,8,15 by 6-h continuous infusion every 28 days. In their study, 11 heavily pre-treated patients with STS were enrolled.The sideeffects were mainly hematological, and the response, i.e. two partial responses and three cases with disease stabilizations, were all in pulmonary metastases. Postponing the inevitable death with a relatively non-toxic treatment is an important issue especially in cases of young patients.
It is clear that no treatment recommendations can be made on the basis of such small series. However, it may be justi® ed and warranted to investigate the activity of gemcitabine in a larger group of patients with bone sarcomas, even as a ® rst line treatment for recurrent or metastatic disease.
